84 related articles for article (PubMed ID: 24328701)
1. Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model.
Gupta A; Nair A; Kumria R; Al-Dhubiab BE; Chattopadhyaya I; Gupta S
J Med Food; 2013 Dec; 16(12):1095-100. PubMed ID: 24328701
[TBL] [Abstract][Full Text] [Related]
2. Spirulina protects against rosiglitazone induced osteoporosis in insulin resistance rats.
Gupta S; Hrishikeshvan HJ; Sehajpal PK
Diabetes Res Clin Pract; 2010 Jan; 87(1):38-43. PubMed ID: 19896232
[TBL] [Abstract][Full Text] [Related]
3. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of pioglitazone in Thai healthy subjects.
Wittayalertpanya S; Chompootaweep S; Thaworn N
J Med Assoc Thai; 2006 Dec; 89(12):2116-22. PubMed ID: 17214065
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions with thiazolidinediones.
Scheen AJ
Clin Pharmacokinet; 2007; 46(1):1-12. PubMed ID: 17201456
[TBL] [Abstract][Full Text] [Related]
7. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
8. Effect of raw Radix Rehmanniae on the pharmacokinetics of pioglitazone in rats.
Shi Z; Gao J; Yuan Y; Zhu S; Yao M
Pak J Pharm Sci; 2014 May; 27(3):537-9. PubMed ID: 24811814
[TBL] [Abstract][Full Text] [Related]
9. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
[TBL] [Abstract][Full Text] [Related]
10. Herb-drug pharmacokinetic interaction between radix astragali and pioglitazone in rats.
Yuan YM; Gao JW; Shi Z; Huang P; Lu YS; Yao MC; Huang M
J Ethnopharmacol; 2012 Nov; 144(2):300-4. PubMed ID: 23026308
[TBL] [Abstract][Full Text] [Related]
11. Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats.
Varanasi KK; Potharaju S; Rajak S; Veeraraghavan S; Mallick P; Vakkalanka SK
Methods Find Exp Clin Pharmacol; 2008 Sep; 30(7):537-42. PubMed ID: 18985182
[TBL] [Abstract][Full Text] [Related]
12. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
13. Alterations in beta-islets of Langerhans in alloxan-induced diabetic rats by marine Spirulina platensis.
Muthuraman P; Senthilkumar R; Srikumar K
J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1253-6. PubMed ID: 19912059
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cinnamomum cassia on the Pharmacokinetics and Pharmacodynamics of Pioglitazone.
Mamindla S; Koganti VSRGP; Ravouru N; Koganti B
Curr Clin Pharmacol; 2017; 12(1):41-49. PubMed ID: 28176623
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
[TBL] [Abstract][Full Text] [Related]
16. Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.
Sengupta P; Nandi U; Pal TK
Regul Toxicol Pharmacol; 2012 Feb; 62(1):7-15. PubMed ID: 22203042
[TBL] [Abstract][Full Text] [Related]
17. Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):919-25. PubMed ID: 16405447
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of pioglitazone in lean and obese cats.
Clark MH; Hoenig M; Ferguson DC; Dirikolu L
J Vet Pharmacol Ther; 2012 Oct; 35(5):428-36. PubMed ID: 22612529
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
Zhang M; Gao X; Bai SJ; Ye XM; Zhang J
Eur Rev Med Pharmacol Sci; 2014; 18(9):1307-14. PubMed ID: 24867508
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
